Cited by 33Adrenal Hormones and DisordersAdipokines, Inflammation, and Metabolic DiseasesDiabetes, Cardiovascular Risks, and Lipoproteins

Glucocorticoid treatment impairs microvascular function in healthy men in association with its adverse effects on glucose metabolism and blood pressure: A randomised controlled trial

Open access
van Raalte, Daniël H., Diamant, Michaela, Ouwens, D. Margriet, Ijzerman, Richard G., Linssen, Margot M. L., Guigas, Bruno, Eringa, Etto C., Serné, Erik H.·2013·Diabetologia

Abstract

Aims/hypothesis Glucocorticoids (GCs) are widely used anti-inflammatory agents that frequently induce side effects, including insulin resistance, diabetes and hypertension. Here, we investigated the contribution of microvascular dysfunction to the development of these adverse effects in healthy men.Methods In a randomised, placebo-controlled, dose-response intervention study, 32 healthy normoglycaemic men (age: 21 ± 2 years; BMI: 21.9 ± 1.7 kg/m(2)) were allocated to receive prednisolone 30 mg once daily (n = 12), prednisolone 7.5 mg once daily (n = 12) or placebo (n = 8) for 2 weeks using block randomisation. A central office performed the treatment allocation, and medication was dispersed by the hospital pharmacy that was also blinded. Treatment allocation was kept in concealed envelopes. Participants, study personnel conducting the measures and assessing the outcome were blinded to group assignment. The study was conducted at a university hospital. Primary endpoint was prednisolone-induced changes in microvascular function, which was assessed by capillary microscopy. Insulin sensitivity was determined by hyperinsulinaemic-euglycaemic clamp and postprandial glycaemic excursions by standardised meal tests.Results Compared with placebo, prednisolone 7.5 mg and 30 mg decreased insulin-stimulated capillary recruitment by 9 ± 4% and 17 ± 3%, respectively (p < 0.01). In addition, prednisolone 7.5 mg and 30 mg reduced insulin sensitivity (M value) by -11.4 ± 4.5 μmol kg(-1) min(-1) and -25.1 ± 4.1 μmol kg(-1) min(-1) (p < 0.001) and increased postprandial glucose levels by 11 ± 5% and 27 ± 9% (p < 0.001), respectively. Only high-dose prednisolone increased systolic blood pressure (6 ± 1.2 mmHg, p = 0.006). Prednisolone-induced changes in insulin-stimulated capillary recruitment were associated with insulin sensitivity (r = +0.76; p < 0.001), postprandial glucose concentrations (r = -0.52; p < 0.03) and systolic blood pressure (r = -0.62; p < 0.001). Prednisolone increased resistin concentrations, which were negatively related to insulin-stimulated capillary recruitment (r = -0.40; p = 0.03). No effects were noted on adiponectin and leptin concentrations. Prednisolone treatment was well tolerated; none of the participants left the study.Conclusions/interpretation Prednisolone-induced impairment of insulin-stimulated capillary recruitment was paralleled by insulin resistance, increased postprandial glucose levels, hypertension and increased circulating resistin concentrations in healthy men. We propose that GC-induced impairments of microvascular function may contribute to the adverse effects of GC treatment on glucose metabolism and blood pressure.Trial registration isrctn.org ISRTCN 78149983.Funding The study was funded by the Dutch Top Institute Pharma T1-106.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-013-3016-8

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Whether steroid-sparing regimens lower posttransplant diabetes risk remains unclear, with mixed study results.

    “It is still unclear if steroid-sparing regimens decrease the risk of PTDM with studies showing mixed results.1591–1595”

    From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1595]

    The Results and Discussion report that prednisolone worsened glucose metabolism in healthy men. Searches for steroid-sparing regimens and posttransplant diabetes found no passage assessing diabetes risk in transplant recipients or reporting mixed results from regimen studies. The cited paper therefore does not address the claim. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 36 · Cited by 33

Authors
van Raalte, D. H., Diamant, M., Ouwens, D. M., Ijzerman, R. G., Linssen, M. M. L., Guigas, B., Eringa, E. C., & Serné, E. H.
Affiliations
  • Deutsches Diabetes-Zentrum e.V. (DE)
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
  • Leiden University Medical Center (NL)
  • Amsterdam Cardiovascular Sciences (NL)
Venue
Diabetologia
Published
2013-08-11
Volume
56
Issue
11
Pages
2383-2391
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W2048992261
Cited by
33
References
36
Citations by year
2026: 3 · 2025: 2 · 2024: 3 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 2 · 2018: 4 · 2017: 3 · 2016: 2 · 2015: 2 · 2014: 3
FWCI
1.84
Type
journal article
Language
en
Open access
Locations
  • Diabetologia (publishedVersion)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
Funders
Top Institute Pharma
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
glucocorticoids, prednisolone, microvascular dysfunction, capillary recruitment, insulin sensitivity, insulin resistance, postprandial blood glucose, glucose metabolism, hypertension, blood pressure, dose-response relationship, healthy men, adverse drug reactions, hyperglycemia, capillaroscopy, hyperinsulinemic-euglycemic clamp, test meal, anti-inflammatory agents
MeSH terms
Adult, Anti-Inflammatory Agents, Blood Glucose, Blood Pressure, Glucocorticoids, Humans, Male, Prednisolone, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review